Hologic's Aptima HPV Assay Receives US FDA Approval for Primary Cervical Cancer Screening
US FDA approves Hologic’s mRNA-based Aptima HPV assay for clinician-collected primary screening, expanding cervical cancer testing options and enhancing early detection of high-risk infections.
Hologic | 07/02/2026 | By News Bureau | 141
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy